Multiple Sclerosis in Childhood and Adolescence: Clinical Features and Management

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2001 Jun 8

PMID 11393326

Citations 4

Authors

O Pinhas-Hamiel

I Sarova-Pinhas

A Achiron

Affiliations

Soon will be listed here.

Abstract

The presentation of multiple sclerosis (MS) in childhood has traditionally been thought to be rare. However, more paediatric cases are now being reported, as a result of progress in diagnostic techniques with the use of sensitive imaging modalities of the brain and spinal cord. Management from an early age and the availability of new treatment options have changed the outcome of paediatric MS. Drugs currently available for treatment, such as beta-interferons, copolymer-1 and intravenous immunoglobulin G, have been found to reduce relapse rate, disease severity and progression to disability in adults, but have not been investigated in children and adolescents. The overall outcome of MS in children is apparently no worse than in adults and the disease may even be less aggressive in children. In juvenile MS, disease progression does not appear to be related to age of onset, severity of neurological involvement or mono/polysymptomatic involvement at presentation. The potential to treat MS has significantly changed the prognosis. Early diagnosis is important, as early treatment can prevent or delay the development of disability.

Citing Articles

Cognitive dysfunction in pediatric multiple sclerosis.

Suppiej A, Cainelli E Neuropsychiatr Dis Treat. 2014; 10:1385-92.

PMID: 25092984 PMC: 4114903. DOI: 10.2147/NDT.S48495.

Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.

Hojjati S, Hojjati S, Baes M, Bijani A Caspian J Intern Med. 2014; 5(1):5-8.

PMID: 24490005 PMC: 3894462.

Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.

Ghezzi A, Amato M, Capobianco M, Gallo P, Marrosu M, Martinelli V Neurol Sci. 2007; 28(3):127-32.

PMID: 17603763 DOI: 10.1007/s10072-007-0804-2.

[Bilateral uveitis intermedia. A 15-year clinical course].

Ayertey H, Jordan J, Walter P, Brunner R Ophthalmologe. 2004; 100(12):1106-8.

PMID: 14704828 DOI: 10.1007/s00347-003-0793-3.

References

Kohler B, TZONOS T, Gustorf R, Okazaki H . [Bilateral cysts of the brain, an unusual manifestation of multiple sclerosis in childhood (author's transl)]. Klin Padiatr. 1980; 192(3):275-80. DOI: 10.1055/s-2008-1035593. View

Kriss A, Francis D, Cuendet F, Halliday A, Taylor D, Wilson J . Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry. 1988; 51(10):1253-8. PMC: 1032910. DOI: 10.1136/jnnp.51.10.1253. View

Miller D, Robb S, Ormerod I, Pohl K, MacManus D, Kendall B . Magnetic resonance imaging of inflammatory and demyelinating white-matter diseases of childhood. Dev Med Child Neurol. 1990; 32(2):97-107. DOI: 10.1111/j.1469-8749.1990.tb16909.x. View

Weinstock-Guttman B, Jacobs L . What is new in the treatment of multiple sclerosis?. Drugs. 2000; 59(3):401-10. DOI: 10.2165/00003495-200059030-00002. View

Riikonen R, Donner M, ERKKILA H . Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children. Dev Med Child Neurol. 1988; 30(3):349-59. DOI: 10.1111/j.1469-8749.1988.tb14560.x. View

Ghezzi A, Martinelli V, Torri V, Zaffaroni M, Rodegher M, Comi G . Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999; 246(9):770-5. DOI: 10.1007/s004150050453. View

Zhang I, Raus J . T cell vaccination in multiple sclerosis. Mult Scler. 1996; 1(6):353-6. DOI: 10.1177/135245859600100615. View

Bye A, Kendall B, Wilson J . Multiple sclerosis in childhood: a new look. Dev Med Child Neurol. 1985; 27(2):215-22. DOI: 10.1111/j.1469-8749.1985.tb03772.x. View

Pinhas-Hamiel O, Barak Y, Siev-Ner I, Achiron A . Juvenile multiple sclerosis: clinical features and prognostic characteristics. J Pediatr. 1998; 132(4):735-7. DOI: 10.1016/s0022-3476(98)70371-3. View

10.

Rizzo 3rd J, Lessell S . Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988; 38(2):185-90. DOI: 10.1212/wnl.38.2.185. View

11.

Hanefeld F, Bauer H, Christen H, Kruse B, Bruhn H, Frahm J . Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 1991; 13(6):410-6. DOI: 10.1016/s0387-7604(12)80038-6. View

12.

Kil K, Zang Y, Yang D, Markowski J, Fuoco G, Vendetti G . T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999; 98(2):201-7. DOI: 10.1016/s0165-5728(99)00057-0. View

13.

Adams A, Tyor W, Holden K . Interferon beta-1b and childhood multiple sclerosis. Pediatr Neurol. 1999; 21(1):481-3. DOI: 10.1016/s0887-8994(99)00007-7. View

14.

Haller P, Patzold U . [Optic neuritis in childhood (author's transl)]. Fortschr Neurol Psychiatr Grenzgeb. 1979; 47(4):209-16. View

15.

Beck R, Cleary P, Anderson Jr M, Keltner J, Shults W, Kaufman D . A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326(9):581-8. DOI: 10.1056/NEJM199202273260901. View

16.

Ruggieri M, Polizzi A, Pavone L, Grimaldi L . Multiple sclerosis in children under 6 years of age. Neurology. 1999; 53(3):478-84. DOI: 10.1212/wnl.53.3.478. View

17.

Shaw C, Alvord Jr E . Multiple sclerosis beginning in infancy. J Child Neurol. 1987; 2(4):252-6. DOI: 10.1177/088307388700200403. View

18.

Lucchinetti C, Kiers L, ODuffy A, Gomez M, Cross S, Leavitt J . Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology. 1997; 49(5):1413-8. DOI: 10.1212/wnl.49.5.1413. View

19.

MATTYUS A, Veres E . Multiple sclerosis in childhood: long term katamnestic investigations. Acta Paediatr Hung. 1985; 26(3):193-204. View

20.

Sorensen P, Wanscher B, Jensen C, Schreiber K, Blinkenberg M, Ravnborg M . Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998; 50(5):1273-81. DOI: 10.1212/wnl.50.5.1273. View